$59.84
0.71% yesterday
NYSE, May 20, 10:00 pm CET
ISIN
US2074101013
Symbol
CNMD

Conmed Corp. Target price 2025 - Analyst rating & recommendation

Conmed Corp. Classifications & Recommendation:

Buy
29%
Hold
71%

Conmed Corp. Price Target

Target Price $64.14
Price $59.84
Potential
Number of Estimates 7
7 Analysts have issued a price target Conmed Corp. 2026 . The average Conmed Corp. target price is $64.14. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 7 analysts: 2 Analysts recommend Conmed Corp. to buy, 5 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Conmed Corp. stock has an average upside potential 2026 of . Most analysts recommend the Conmed Corp. stock at Hold.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Billion $ 1.30 1.36
4.98% 4.47%
EBITDA Margin 16.54% 20.31%
12.69% 22.76%
Net Margin 10.09% 8.84%
98.45% 12.39%

7 Analysts have issued a sales forecast Conmed Corp. 2025 . The average Conmed Corp. sales estimate is

$1.4b
Unlock
. This is
3.85% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.4b 4.31%
Unlock
, the lowest is
$1.4b 3.03%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $1.3b 4.98%
2025
$1.4b 4.47%
Unlock
2026
$1.4b 5.61%
Unlock
2027
$1.5b 5.07%
Unlock

6 Analysts have issued an Conmed Corp. EBITDA forecast 2025. The average Conmed Corp. EBITDA estimate is

$276m
Unlock
. This is
39.60% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$285m 44.12%
Unlock
, the lowest is
$267m 35.03%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $216m 18.30%
2025
$276m 28.22%
Unlock
2026
$292m 5.52%
Unlock
2027
$314m 7.81%
Unlock

EBITDA Margin

2024 16.54% 12.69%
2025
20.31% 22.76%
Unlock
2026
20.29% 0.10%
Unlock
2027
20.82% 2.61%
Unlock

4 Conmed Corp. Analysts have issued a net profit forecast 2025. The average Conmed Corp. net profit estimate is

$120m
Unlock
. This is
1.83% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$140m 18.32%
Unlock
, the lowest is
$99.0m 16.23%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $131m 108.33%
2025
$120m 8.47%
Unlock
2026
$137m 13.81%
Unlock
2027
$152m 10.90%
Unlock

Net Margin

2024 10.09% 98.45%
2025
8.84% 12.39%
Unlock
2026
9.53% 7.81%
Unlock
2027
10.06% 5.56%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 4.25 3.89
108.33% 8.47%
P/E 15.38
EV/Sales 1.99

4 Analysts have issued a Conmed Corp. forecast for earnings per share. The average Conmed Corp. EPS is

$3.89
Unlock
. This is
1.83% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$4.52 18.32%
Unlock
, the lowest is
$3.20 16.23%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $4.25 108.33%
2025
$3.89 8.47%
Unlock
2026
$4.43 13.88%
Unlock
2027
$4.91 10.84%
Unlock

P/E ratio

Current 15.68 45.19%
2025
15.38 1.91%
Unlock
2026
13.52 12.09%
Unlock
2027
12.19 9.84%
Unlock

Based on analysts' sales estimates for 2025, the Conmed Corp. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.07 20.08%
2025
1.99 3.87%
Unlock
2026
1.88 5.31%
Unlock
2027
1.79 4.82%
Unlock

P/S ratio

Current 1.41 22.79%
2025
1.36 3.71%
Unlock
2026
1.29 5.31%
Unlock
2027
1.23 4.82%
Unlock

Current Conmed Corp. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JP Morgan
Locked
Locked
Locked May 01 2025
Needham
Locked
Locked
Locked May 01 2025
Wells Fargo
Locked
Locked
Locked May 01 2025
Stifel
Locked
Locked
Locked Apr 28 2025
JP Morgan
Locked
Locked
Locked Feb 06 2025
Needham
Locked
Locked
Locked Feb 06 2025
Stifel
Locked
Locked
Locked Feb 06 2025
Analyst Rating Date
Locked
JP Morgan:
Locked
Locked
May 01 2025
Locked
Needham:
Locked
Locked
May 01 2025
Locked
Wells Fargo:
Locked
Locked
May 01 2025
Locked
Stifel:
Locked
Locked
Apr 28 2025
Locked
JP Morgan:
Locked
Locked
Feb 06 2025
Locked
Needham:
Locked
Locked
Feb 06 2025
Locked
Stifel:
Locked
Locked
Feb 06 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today